---
title: "Aspire Biopharma posts investor deck on sublingual drug-delivery platform, lead sublingual aspirin program"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290583081.md"
description: "Aspire Biopharma announced a USD 30 million cash acquisition of Dura Driver Control Systems, adding significant revenue and patent assets. Concurrently, the company highlighted its sublingual drug-delivery platform, noting that lead program OTASA completed trials with faster therapeutic exposure than chewed tablets. FDA feedback supports a 505(b)(2) filing in Q1 2027. Additionally, consumer product BUZZ BOMB launched in Q3 2025 with distribution agreements."
datetime: "2026-06-23T14:59:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290583081.md)
  - [en](https://longbridge.com/en/news/290583081.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290583081.md)
---

# Aspire Biopharma posts investor deck on sublingual drug-delivery platform, lead sublingual aspirin program

-   Aspire Biopharma outlined plans to acquire Dura Driver Control Systems for USD 30 million in cash, adding a business with 2025 revenue above USD 200 million. \* Dura reported 2025 net income above USD 17 million, adjusted EBITDA above USD 22 million, operations across 11 facilities, portfolio of 310+ patents. \* Lead prescription program OTASA 162 mg sublingual aspirin completed a July 2025 trial, showing therapeutic exposure at least five times faster than chewed tablets. \* FDA feedback supports a 505(b)(2) filing in Q1 2027; IND planned for September; 32-subject crossover trial targeted for completion by end-2026. \* Consumer product BUZZ BOMB caffeine launched in Q3 2025; 50 mg sublingual powder format; distribution agreements cited with Amazon, TruLife, Interwest Brokerage. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief on June 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ASBP.US](https://longbridge.com/en/quote/ASBP.US.md)
- [AMZN.US](https://longbridge.com/en/quote/AMZN.US.md)
- [ASBPW.US](https://longbridge.com/en/quote/ASBPW.US.md)

## Related News & Research

- [James Michael Morrissey Expands Holdings With $54K Incyte Stock Options Acquisition](https://longbridge.com/en/news/294085325.md)
- [GLP-1 drugs could reduce long-term sick leave: Study](https://longbridge.com/en/news/293847884.md)
- [Compounded GLP-1 drugs creating concern among doctors and FDA](https://longbridge.com/en/news/293924807.md)
- [Incyte expects Opzelura to cross $1B in 2026](https://longbridge.com/en/news/294223769.md)
- [Keymed’s CLDN18.2 Drug CMG901 Delivers Phase III Survival Gain in Gastric Cancer](https://longbridge.com/en/news/294008140.md)